Home

Lai Wang

CIK 1852291 · President, Global Head of R&D · last filed 2026-06-25

Lai Wang is a President, Global Head of R&D who has filed 49 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $295.6K of ONC on Jun 25, 2026. Across all open-market trades the lifetime net is −$10.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $215.7M across reported positions. 50 SEC filings were submitted jointly with BeiGene, Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$215.66M

Companies

2

Total Filings

49

Lifetime Open-Market Net

-$9.98M

Filer Profile

Reported Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
94 SOLARIS AVE, CAMANA BAY, PO BOX 1348
GRAND CAYMAN
Related Filers
BeiGene, Ltd. — 50 joint filings, latest 2026-06-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ONC President, Global Head of R&D 601,965 $358.26 $215.66M -$6.77M 15 2026-06-25
BeOne Medicines Ltd. (BGNE) Delisted Global Head of R&D 1,717,885 $184.71 $317.31M -$3.21M 16 2024-10-01

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 ONC Sell (S) −1,068 -$295.6K EDGAR
2026-06-23 — Notice (144) −1,068 -$295.6K EDGAR
2026-06-18 ONC Sell (S) −1,169 -$310.2K EDGAR
2026-06-16 — Notice (144) −1,169 -$310.2K EDGAR
2026-06-15 ONC Mixed +117,869 -$197.3K EDGAR
2026-06-11 — Notice (144) −756 -$197.6K EDGAR
2026-06-10 ONC Sell (S) −1,367 -$368.2K EDGAR
2026-06-08 — Notice (144) −1,367 -$368.2K EDGAR
2026-03-10 ONC Grant (A) +167,635 $0 EDGAR
2026-01-05 ONC Grant (A) +427,895 $0 EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.